Protection of mice from Mycobacterium avium infection by recombinant interleukin-12

Treatment with interleukin-12 (IL-12) significantly reduced the number of viable bacteria in mice infected with Mycobacterium avium. IL-12 itself, however, could not inhibit directly mycobacterial growth in vitro. IL-12 exerts antimycobacterial activity in vivo with a low level of toxicity, possibly by enhancing the host defense against the infection.

[1]  G. Trinchieri,et al.  The role of interleukin 12 in the immune response, disease and therapy. , 1994, Immunology today.

[2]  M. Gately,et al.  Interleukin 12 at the site of disease in tuberculosis. , 1994, The Journal of clinical investigation.

[3]  L. Bermudez,et al.  Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. , 1994, The Journal of infectious diseases.

[4]  S. Ehlers,et al.  Progress in TB research: Robert Koch's dilemma revisited. , 1994, Immunology today.

[5]  A. Sher,et al.  Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Schaub,et al.  Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response , 1993, The Journal of experimental medicine.

[7]  H. Maeda,et al.  Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis , 1993, Infection and immunity.

[8]  R. Rerko,et al.  Recombinant interleukin 12 cures mice infected with Leishmania major , 1993, The Journal of experimental medicine.

[9]  P. Scott IL-12: initiation cytokine for cell-mediated immunity. , 1993, Science.

[10]  A. Dannenberg Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. , 1991, Immunology today.

[11]  M. Denis Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteria , 1991, Clinical and experimental immunology.

[12]  M. Denis Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. , 1991, Cellular immunology.

[13]  L. Bermudez,et al.  Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. , 1989, Journal of immunology.

[14]  Kazuo Kobayashi,et al.  The role monokines in granuloma formation in mice: The ability of interleukin 1 and tumor necrosis factor-α to induce lung granulomas , 1989 .

[15]  C. Kirkpatrick,et al.  The immunology of mycobacterial diseases. , 1986, The American review of respiratory disease.

[16]  A. Zlotnik,et al.  Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. , 1986, Journal of immunology.

[17]  T. Tokunaga,et al.  Genetic control of resistance to Mycobacterium intracellulare infection in mice , 1984, Infection and immunity.

[18]  P. Gangadharam,et al.  An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. , 2015, The American review of respiratory disease.

[19]  S. G. Campbell,et al.  Immunity to intracellular bacteria. , 1982, Veterinary immunology and immunopathology.

[20]  S. Watson,et al.  Immune responses to atypical mycobacterial lung infections. , 1981, Reviews of Infectious Diseases.